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Abstract

Introduction

Radioactive gold has properties suitable for radiotherapy and can provide lethal irradiation to cells. If the
gold is conjugated to a targeting molecule, such as an
antibody, it may be possible to specifically deliver the
dose to tumor cells. Various gold particles are possible
candidates and include gold colloids with adsorption of
antibodies or gold clusters with covalent attachment.
Different sizes of gold particles are available and some
may be preferred for certain situations. Problems with
intravenous injection and in vivo delivery are numerous,
and a more tractable application is the direct instillation
into the urinary bladder of radiogold immunoconjugates
to treat superficial bladder carcinoma . Preliminary studies indicate the feasibility of this approach.

Gold technology
Gold is used as a label and has become the preferred marker for electron microscopy due to its high
electron scattering and the development of methods to
produce uniform sizes and conjugate them to a variety of
molecules. Antibodies are adsorbed to colloidal gold
particles in low ionic strength solutions. A further
advance was the use of large multiple gold atom compounds (or clusters), such as the undecagold cluster
(Fig . 1). The organic shell permits covalent attachment
to an Fab' antibody fragment (or other molecule) as
shown in Figure 2 (Hainfeld, 1987, 1989). This adds
stability to the conjugate and serves also to orient the
antibody with the hypervariable region facing outward,
since attachment is via the hinge sulfhydryl. Also, the
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Figure l. The undecagold cluster.
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Figure 2. Covalent coupling
of gold to Fab' fragment at the
hinge sulfhydryl.
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gold clusters may be made monofunctional (Yang et al.,
1984; Safer et al., 1986) so that just one antibody (lgG
or Fab') is attached per gold particle (Fig. 3). In addition, the reactive groups on the gold clusters may be
made to couple to various moieties: a maleimide group
to react with free sulfhydryls, a N-hydroxysuccinimide
ester to couple to amines, or an amino group to link to
aldehydes, which may be formed by oxidizing carbohydrate moieties. Other chemistries are also possible.
Gold technology has developed to the point where
fairly uniform sizes of gold spheres may be prepared.
Colloidal golds may be made that are - 1 to 50 nm in
size; the ones > 5 nm can be quite uniform, but the
smaller sizes show much more variation in size, frequently ~ 100% for 1-2 nm . In contrast , the gold clusters, e.g., Au 11 and Au1.4 nm (Nanogold), are gold
compounds and contain a definite number of gold atoms
(11 or 67, respectively), so their size is extremely
uniform (gold cores of 0.82 nm or 1.4 nm, respectively).
All of these gold particles can be silver enhanced,
leading to higher sensitivity and better visibility. The
small gold particles can then not only be seen in the
electron microscope, but in the light microscope or with
the unaided eye, e.g., on blots developed with silver.

Figure 3. 1.4 nm gold clusters (Nanogold) covalently
attached to Fab' fragments. Thin arrow points to a gold
cluster (white dot), attached to the hinge sulfhydryl of a
Fab' antibody fragment (thicker arrow, grey density
mass). Bar = 20 nm.

Use of gold in diagnosis and therapy
or horseradish peroxidase to produce colored products),
gold conjugates have also been used. Another example
is the home pregnancy test kit that shows a pink positive
color, the pink being -20 nm colloidal gold. Gold of
this size has the unique property of having an extinction
coefficient of - 108 , or about 1000 times more than
most other colored compounds, including fluorescent
ones. This makes a few picomoles of gold directly visible with the unaided eye. Gold particles may also be
silver enhanced to improve the sensitivity even further.

With all of this technology involving gold and immunolabeling, or targeting using lectins or other molecules, one might ask if this could be applied to medical
applications such as cancer diagnosis or therapy. For
diagnosis, gold immunoconjugates could be used to detect tumor antigens from the blood, or to do immunocytochemistry of biopsied material.
Serum detection
schemes usually employ microtiter plate assays, Westerns, or types of dot blots. Although enzyme linked assays are the most common (using alkaline phosphatase
240
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Table 1. Properties of radioactive gold-198 and 199 (Lederer and Shirley , 1986).
t 112(days)

{3- (keV)

'Y, keV (%)

{3- range in water

198Au

2.7

312 (avg.); 961 (max.)

412 (95)

460 µm avg .; 4.0 mm "?ax.

199Au

3.1

86 (avg.); 453 (max.)

159 (37); 208 (22)

100 µm avg .; 1.0 mm max.

the 412 keV of 198Au is higher than normally used for
imaging studies.
Imaging is an important clinical
requirement since different patients respond variably to
antibodies . This means that a low dose could be used to
determine tumor localization and exact dosimetry before
a therapeutic (and potentially hazardous) dose was administered. Only a few elements meet the requirement
of appropriate (low to intermediate) {3 with a 'Y suitable
for imaging : 47sc, 67cu, 105Rh, 1311,153sm, and 198Au
and 199Au (Mausner et al., 1988) and 177Lu . Therefore, radioactive gold turns out to be one of the few best
isotopes for radionuclide therapy. The use of radio gold
solely for diagnostic imaging is not apparently advisable,
since the {3emission would induce tissue damage . Other
isotopes, that emit mainly 'Y rays, are more suitable,
such as 111ln, 99mTc, 201Tl, and 1251, although 1251 does
not have a high enough 'Yenergy for efficient imaging.
Radiogold should therefore be further considered for
therapeutic applications . The basic idea is to target the
gold to tumor cells, which would then be locally irradi ated and die. This modality seems best suited to tracking down small metastases or cells that escape surgery,
and is probably not suited to treating large tumor masses
that can be effectively removed by surgery. Since most
patients with cancer die due to metastatic growths,
where surgery is not effective or possible, this area of
application is important. Many anti-tumor antibodies
have been developed worldwide to pursue immunotherapies. These antibodies may be used either alone, in
hopes of stimulating antibody-dependent cellular cytotoxicity (ADCC) or the complement system, or as conjugates to target a cytotoxic agent (e.g. , ricin), or a radioisotope; boron (or uranium) neutron capture therapy is
yet another variation . Drugs, prodrugs, and coagulantstimulating tissue factors have also been used . Other
targeting molecules besides antibodies are possible and
include peptides , hormones, and growth factors (e.g .,
epidermal growth factor). The avidin-biotin method has
been proposed as a two step targeting procedure, and
gold may be made with either of these molecules
attached .
The usual sequence for testing the effectiveness of
a radioimmunoconjugate is to first test it in vitro (binding to tumor and non-tumor cells grown in cell culture),
check serum stability, then inject it into nude mice

In vivo imaging using gold may someday be possible,
since gold may be sensitively detected using X-ray absorption or X-ray induced X-ray fluorescence . This
would require adequate targeting to tumors and the proper instrumentation. Gold is also sensitively detected by
mass spectrometry (to -1 ppb) or neutron activation , so
that other forms of probe measurements and diagnostic
procedures could be envisioned. Recently, 16 nm colloidal gold stabilized with bovine serum albumin (BSA)
was injected into test animals to test leakage into alveolar lung mucous which would bJ used to diagnose pulmonary leakage (Darien et al., 1995). The lung mucous
samples were analyzed for gold by neutron activation.
For therapy, gold materials might also be useful.
Various gold compounds have been used for some time
to treat arthritis. However, no gold formulations have
yet been found for effective cancer therapy in the same
way as some other organometallics such as cisplatin.

Radioactive gold
Radioactive gold presents an interesting extension to
the usefulness of the rest of gold technology. Several
isotopes are possible, but perhaps the two most useful
ones are 198Au and 199Au. Their properties are shown
in Table 1.
198Au may be produced from neutron irradiation of
natural gold in a research nuclear reactor . However, the
specific activity is limited, i.e., only about 1 in 3,000
gold atoms becomes radioactive with ty~ical irradiation
times and fluxes. No carrier added 1 9Au (where all
gold atoms are radioactive) may be produced from an
enriched 198Pt target, and later purified from the platinum (Anderson et al., 1988; Kolsky and Mausner,
1993) . The 3 day half life is acceptable since it gives
time for preparation and administration, but would not
reside long-term in a patient (avoiding the so-called
"night light" effect). Gold is a low to intermediate
range {3emitter, with a range of several cells. This may
be preferable to the use of 9oy (avg. {3- = 934.8 keV,
max . = 2283.9 keV), for example, which has an average range of 4 mm (1.0 cm max.) and may damage adjacent tissue. One also has the choice of using 198Au or
199Au to optimize the range desired, that of 199Au being
-1/5 of that of 198Au (100 µm versus 460 µm). 198Au
and 199Au also emit 'Y's suitable for imaging, although
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which have human tumor xenografts (formed by injecting human tumor cells subcutaneously which then grow
into a tumor mass). Further animal testing should
include toxicity and antigenicity studies. Favorable
products may go on to human clinical trials.

processing of monoclonal antibodies (MAbs) by these
organs.
Another barrier to effective delivery is the poor penetration of antibodies into tumor masses, due to their
large size (Langmuir et al., 1991). They must pass
through the endothelium of the blood vessels to reach the
first tumor cells, then pass between cells to go to the
next layer . This is not a favorable situation, and explains why the better results with radioimmunotherapy
have been obtained with blood borne lymphomas which
are readily accessible, being already in the blood compartment, than with solid carcinomas. The endothelium
is an interesting barrier, and different tissues have
varying porosity, leading to different tissue specific
macromolecular leakage rates. Fortunately, higher
endothelial leakage is frequently observed in tumor
vasculature (Jain and Gerlowski, 1986). Histological
examination of radioimmunoconjugate localization in
tumors indicates it to be primarily along the blood
vessels and not highly correlated with tumor cell antigen
expression (Esteban et al., 1994). One might propose
smaller targeting molecules, such as F(ab')i, Fab
fragments, single chain antibodies, or peptides to improve tumor penetration. However, a disadvantage of
small molecules has been that for ~ 60,000 daltons (D),
they are rapidly cleared by the kidney and do not allow
adequate tumor accumulation. For imaging, this is an
advantage , since background blood concentration is reduced quickly, and less delivery to the tumor is acceptable. For therapy , F(ab ' )i fragments are considered
best (Yorke et al., 1991), since tumor accumulation
rises for about 22 hours (Andrew et al., 1990), and the
retention time of F(ab ')z in the blood is consistent with
this (whole lgG often shows better tumor uptake at 48
hours). There are also Fe receptors on some cells , and
the use of F(ab')i fragments eliminates this non-specific
binding. Even with all these factors, fairly similar results have been obtained for lgG and F(ab')i.
A further explanation of why so little antibody accumulates on the tumor is the dilution effect. Dye injected
into a river with a dye-binding site downstream on the
shore will only accumulate a small fraction of the material. The mouse to human weight ratio is ~ 2800, so
that, e.g., a 1 g tumor in a mouse with a localization of
20% injected dose per gram (id/g), might be expected in
a human to achieve 1/2800 of this, or 0.007 % id/g, due
to antibody dilution; this is in the range found by clinical
trials (Sands, 1988). The injected immunoconjugates are
spread far and wide and once passing through tissue endothelium, may reside there during the course of study.
Another factor is the antibody itself, its binding constant,
the heterogeneity of tumors , and cross reactivity with
other tissues. Since mouse monoclonals are typically
used, there is the problem of human anti-mouse antibody

Immunotherapy: general problems

Most of the clinical trials in this area to date have
been done with 9oy or 1311 due to their availability and
ease of antibody coupling . Although there have been
some occasional remissions and favorable responses
{e.g., 4 patients out of 9 with B-cell lymphoma had
complete remissions using 1311 anti-CD20 antibody,
(Kaminski et al., 1993)}, the overall success of antibody
therapy (including ADCC, toxin and radioconjugates)
has been disappointing. The main reason for this is the
low tumor to non-tumor localization of the antibody (for
a review of the problems with radioimmunoconjugates,
see: Sands, 1988). Generally, there is high uptake in
the liver, as well as spleen, bone, and frequently kidney.
Although specific tumor uptake is evident, there is frequently a higher amount in other tissues (Reilly , 1991).
In human trials, typically only ~0.007 % of the injected
materials localizes in the tumor (per gram, Sands,
1988), meaning that most of the antibody , radioactivity
or toxins are in other tissues. It takes ~ 10,000 rad to
kill tumor cells (Bigler et al., 1988), but only 500-1,000
rad to lethally damage the bone marrow {serious bone
marrow depression was observed in 21 % of patients receiving bone marrow doses exceeding 200 rad (Bigler et
al., 1988)}. One cannot simply raise the amount injected to kill the tumor , since the lethal dose to other organs
would be exceeded . There are several explanations : for
this lack of good tumor to non-tumor localization: one
is the instability of the radioisotope-antibody conjugate.
Typically, diethylenetriaminepentaacetic acid (DTPA)
chelators have been covalently attached to lgG's which
then chelate the radiometal. Each chelator has a dissociation constant for the metal-chelator complex, and there
is a finite release rate of the metal. Once released, a
metal ion can bind to other serum components or may
have natural affinity for particular organs; e.g., yttrium
goes to bone, indium goes to the liver, and iodine to the
thyroid. Chelation chemistry has improved and highly
stable conjugates are now available which virtually eliminate this problem (Li and Meares , 1993). A second
effect is that the conjugates are not native molecules and
may be removed by the liver; this is particularly true
with lgG aggregates, colloids, liposomes (Allen, 1994),
and perhaps other more native looking constructs.
Aggregated antibodies lead to increased liver uptake, but
more careful chromatographic separation permits only
monomers to be selected for use. Another important
factor in liver and spleen uptake is due to the antibody
242
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Fi2ure 4.
Production of
198Au and 199Au from neutron
irradiation of natural gold.
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forming (the HAMA response), which may hinder multiple treatments. The search for better antibodies, their
genetic manipulation and humanization has improved this
aspect to some extent (Buist et al., 1995). Unfortunately, with all of these negative factors, adequate tumor to
non-tumor ratios for effective therapy in humans has
generally not been achieved.
Radiogold immunotherapy of bladder carcinoma,
first proposed by de Harven et al. (1992), avoids most
of the above difficulties and is discussed later.
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Results Using Radioactive Gold
Preparation of low-specific activity Au-198

0
100

We have studied the use of gold as the radioisotope
for potential therapy (Hainfeld et al., 1990). The first
aspect is the production of the radioactive gold. Neutron
irradiation of clusters or antibody-gold conjugates directly was avoided, since samples must be dried, sealed in
a vacuum, and beam heating may approach 400°C.
Gold metal was therefore irradiated, and synthesis of
gold clusters or gold colloids was done after activation .
The following activation reaction (Fig. 4) describes the
preparation of 198Au from natural Au-197:
Irradiation times used were typically 2 to 8 hours at
a neutron flux of 8 x 1014 neutrons/cm 2 ·s; the sample
size was 2 mg, and the product was low-specific activity
gold, ~ 80 mCi/mg, which is equivalent to ~ 1 in 3,000
of the gold atoms being radioactive . About 90 % of the
radiogold produced is 198Au, and about 10% 199 Au.
Although the radioactive gold eventually decays to
mercury, the amount of mercury produced in vivo for
therapeutic doses of gold is far below chemical toxicity
levels.

25
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Figure 5. Cell binding assay using 17-lA F(ab')i -Auu
compared to native F(ab')i.
cleared from the blood by the liver. Gold atoms do not
bind to the standard chelates (such as DTPA) used in
this type of work with other radiometals , but covalent
linking of gold clusters has been demonstrated to be feasible and stable, and they can be prepared in high yield.
Undecagold clusters covalently bound to IgG, F(ab')i,
or Fab' fragments were tested . The monoclonal antibody 17-lA, reactive with human colon carcinomas was
used and the target cells were LS180; control cells were
a melanoma line, WM164. The gold labeled antibodies
showed high retention of immunoreactivity on cell binding assays: 76% for Fab'-Auu, 80% for F(ab')i-Aull,
and 83 % for IgG-Au 11 , using non-radioactive gold and
a second antibody (goat anti-mouse) labeled with 1251.
An example is shown in Figure 5. In these second antibody assays, the labeling with gold cluster was close to
100% (one gold cluster per antibody), so that the results
should, in fact, be measuring activity of the conjugate
and not of the native antibody.

In vitro tumor cell binding of gold immunoconjugates
Since much of our work was directed toward intravenous administration of the immunoconjugate for targeting of carcinomas, the use of gold colloids was
avoided, since other colloids are known to be rapidly
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Table 2. Cell binding of radiogold antibody conjugates
to tumor and control cells. Results are expressed as the
percent of applied radioactivity remaining with the cells
after washing.

Sample

Fab'-Aull

% bound to
tumor cells

% bound to
control cells

7.8 ± 0.5

1.9 ± 0.2

±

F(ab')z-Aull

16.1

0.1

0.3 ± 0.1

IgG-Au 11

14.3 ± 0.9

0.8 ± 0.1

0.5 ± 0.1

0.5 ± 0.1

Au 11

In vitro cell binding of radioactive

accuracy. Nude mice (which are immunodeficient) with
the target human tumor implanted (a xenograft) are used
to determine tumor localization. Human tumor cells
grown in culture are injected subcutaneously, usually in
the shoulder area, and after 2 to 3 weeks develop into a
solid tumor mass about 0.5 gin size, complete with vascularization. While not a perfect model, it does permit
human tumors to be used in vivo with the appropriate
anti-human tumor antibody. Radiolabeled antibodies
generally reach a maximal tumor uptake at - 20 hours
(Andrew et al., 1990), with slow washout after several
days, whereas other tissues generally show quicker depletion, although liver and bone can show stable uptake;
because of these pharmacokinetics, time points a few
minutes or hours after injection are not usually taken.
Radioactive undecagold clusters covalently conjugated to monoclonal antibody 17-lA injected into nude
mice with human tumor xenografts gave the biodistributions shown in Table 3. 111Indium-DTPA conjugate results are also shown for comparison using the same antibody .
From these data, several features are evident: the localization of undecagold ( 198Au)-antibodies generally
mimicked the distribution of the 111 indium conjugate,
but bone uptake was significantly lower with the gold
(2.9 times less for the IgG conjugate). Also, the tumor
localization and the tumor to non-tumor ratios were better for the F(ab)' 2 -Au 11 than the F(ab)' rln. Both conjugates showed high kidney accumulation, especially for
the antibody fragments, partially because of their small
size; however, the gold showed higher kidney uptake in
all cases. Effective therapy could be achieved with tumor to non-tumor ratios of 10-50; here values of 0 .5 to
11. 6 were obtained with the IgG-Au 11 , thus falling short
of the required distribution. Generally speaking, this
has been the experience with immunotherapy, both with
radioisotopes and toxin conjugates : biodistributions are
not favorable enough.

undecagold

immunoconjugates

Next, radioactive gold clusters were used, and the
binding to tumor and control cells was measured by
,--counting the gold directly (no second antibody was
used). Microtiter plates were used that contained equal
numbers of cells with various dilutions of undecagold
immunoconjugates. After incubation with the cells for
1 hour, the plates were centrifuged, the supernatant removed, and fresh buffer applied (radioimmunoassay buffer, or "RIA", which is phosphate buffered saline plus
5 % horse serum). Cells were resuspended, then spun
again. Three such washes were done so as to remove
any unbound antibody/gold . Since the total amount of
gold applied was known , the remaining bound gold may
be quantified. Typical results are shown in Table 2.
Good specificity is shown, and was maximal for the
F(ab')z-Au 11 . The Au 11 by itself showed only a background level , and did not appear to have any significant
cellular uptake. The reasons that the specific uptake is
not 100% are : the antibody-antigen binding is in equilibrium, immunoreactivity being < 100 % , incomplete
labeling and competition by native antibody, or other
factors. Cell binding of 15-20% is not uncommon for
many radiolabeled antibodies in this form of assay.

Use of multiple gold atom clusters and high-specific
activity 199Au

One aspect of the use of gold clusters is that more
than one radioactive atom could be delivered per antibody. This could be very important since most radioirnmunotherapy trials have failed due to poor tumor to
non-tumor ratios. In simple one-step delivery schemes,
where the radiolabeled antibody is administered, putting
more radioisotopes per antibody would not be expected
to improve the tumor to non-tumor targeting. Although
more radioactivity may be delivered to the tumor, improved therapy would not be achieved, since more doses
would also be delivered to non-tumor tissues. Generally, the tumor antigen sites are not saturated, and the
additional dose could be just as well delivered by more

In vivo targeting of radioactive gold cluster (Au 11)
immunoconjugates in nude mice with human tumor
xenografts

A second level of testing for tumor targeting is to
inject the preparation into mice, usually intravenously,
through a tail vein. After various times, the mice are
euthanized (killed) and dissected, and the different tissues and organs are placed in separate containers,
weighed and counted. This then gives the biodistribution in vivo of the radioisotope. Time points are usually
24 and 96 hours, with additional points as necessary .
Three or four mice are used per data point for statistical
244
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Table 3. Biodistribution in nude mice with human tumor xenografts 24 hours after injection of radiogold and 111In conjugates. Values are expressed as percent injected dose per gram of tissue.
Fab'-Au

Tissue

F(ab)'rAu

11

± 0.6
5.6 ± 0.4
6.4 ± 0.8
0.93 ± 0. 19
117.
± 20.
3.2 ± 0.4
4.6 ± 0.1
0.98 ± 0.08
2.4 ± 0.2
1.6 ± 0.2
10.5 ± 0.4

± 1.1
3.4 ± 0.3
2.8 ± 0.4
0.57 ± 0.14
103.
± 32.
1.7 ± 0.1
2.5 ± 0.04
0.48 ± 0.06
0.97 ± 0.02
1.3 ± 0. 1
5.6 ± 0.5
6.4

Tumor
Blood
Spleen
Stomach
Kidneys
Heart
Lung
Muscle
Bone
Gut
Liver

lgG-Au 11

F(ab)'rln

11

8.4

5.0
5.8
7.2
1.0
42.0
3.5
5.1
1.0
3.4
1.8
10.6

±
±
±
±
±
±
±
±
±
±
±

3.2
0.2
0.1
0.3
2.1
0.3
0.8
0.1
0.7
0.3
0.7

±
3.2 ±
9.5 ±
0.69 ±
17.1 ±
2.6 ±
3.4 ±
0.80 ±
2.2 ±
1.1 ±
4.6 ±
8.0

±
4.9 ±
13.9 ±
1.1 ±
10.2 ±
2.9 ±
4.1 ±
0.90 ±
6.4 ±
2.0 ±
7.9 ±

3.2

11.1

0.6
0.3
0.20
3.1
0.4
0.9
0.23
0.3
0.3
0.7

Table 4. Irradiation conditions and radiochemical yields for no-carrier added
Target

lgG-In

199Au

2.2
6.4
0.3
0.5
1.0
0.8
0.17
1.8
0.3
2.3

Production .

Irradiation Time (d)

Irradiation Yield (EOE)

Radiochemical Recovery,.

198Pt

(3.98 mg)b

3.43

34.63 GBq (936 mCi)

60%

198Pt

(6.00 mg)b

5.00

77.03 GBq (2082 mCi)

85%

198Pt

(6.20 mg)b

5.00

102.1 GBq (2761 mCi)

98%

3.97

26.46 GBq (751 mCi)

96%

198

Pt (9.94 mgt

bHFIR, Oak Ridge National Lab (fn = 0.95 - 2.15 x 1015 n/cm 2 ·sec)
cHFBR, Brookhaven National Lab (fn = 4.20 x 1014 n/cm 2 ·sec)

198

1.7

crn=3.8 b

Pt----►
-

n,y

199

~

•Measured after Au/Pt separation .
~

1~

Pt ------►- Au
t 112 =30.8 m

t 112 =3.14

Figure 6. Preparation of high-specific activity
singly labeled radioantibody being administered, if
desired. However, more selective targeting schemes that
seek to improve tumor to non-tumor ratios, e.g., using
2 and 3 step procedures (A targets tumor, then radioactive B targets A), generally suffer from a loss of total
tumor uptake of the radioisotope, due to limiting antigens or shorter uptake time periods. Packing more radioactive atoms per antibody could overcome this problem. Gold clusters provide a way of attaching 11 or 67
gold atoms covalently to antibodies without significant
loss of immunoreactivity .
Another issue inherent in achieving this objective of
delivering more radioactive atoms per antibody, is that
the specific activity of the atoms must be high, or near

►

days

1~

Hg

199Au.

no-carrier -added (NCA) material must be used . The
previous method described for preparing Au-198/199
from direct neutron irradiation of natural gold is not
suitable for making high-specific activity gold.
Preparation of high-specific activity 199Au
The highest specific activity Au ( -208 mCi/ µ,g) can
be achieved by irradiating enriched 198Pt (Fig. 6). Only
- 10-5 is converted to 199Au, and the gold must therefore be purified from the platinum. The amount of
199Au needed for a typical set of experiments is at least
300 mCi, or 1.5 µ,g of gold at 208 mCi/µ,g. The pro duction scheme was designed around these criteria.
Methods to purify the Au from the Pt were quantita245
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tively explored using various extraction and chromatography schemes (Anderson et al., 1988; Kolsky and
Mausner, 1993). A tributyl phosphine (TBP)-coated silica column gave the best (and most rapid) separation and
radiochemical yields were > 96 % with a > 105 separation factor (Table 4). Yields were improved from 60 to
> 96 % by making the silica support media used in the
separation hydrophobic. Because traces of TBP were
found in the final solution (15 ml, 14 N HN0:3), the solutions are now evaporated to dryness on a hot plate to
remove the TBP, and the 199Au then is redissolved in
aqua regia. Apparatus was built to handle this separation remotely, and is now used routinely to produce very
pure NCA 199Au ( ~2 Ci at 208 µCilµg per run).
Specific activities were calculated for all of the production runs. They averaged ~98% (205.6 µCilµg) of
the theoretical value (208 µCi/ µg).

a column with a 3,000 molecular weight exclusion limit.
Since the weight of the Au 11 cluster is ~5,000, any
breakdown would be shown by trailing peaks. The
high-specific activity cluster was tested immediately after
its initial synthesis and purification, at which time it behaved normally (identical to a non-radioactive gold cluster). An aliquot was tested after 1 day and after 3 days;
there was about a 5 % degradation after 3 days . For
comparison, the high-specific activity 199Au was mixed
with an 11-fold excess of non-radioactive gold, so that
upon cluster synthesis, each Au 11 cluster contained only
one radioactive gold atom (rather than 11). This cluster
showed virtually no change after 3 days.
These experiments demonstrated acceptable stability
of high;-specific activity clusters, an important step in
validating the potential use of gold clusters for thernpy.

Synthesis of clusters using 1 µg of gold

gates: cell binding

High-specific activity 199Au cluster-antibody conju-

To test high-specific activity 199Au (where nearly all
gold atoms are radioactive), it is necessary to use
~2,000 fold smaller reaction amounts than used previously. Otherwise, the radioactivity would exceed the 1
Curie level and be very difficult to handle. Previously,
2 mg of gold was typically used for a test run. Scaling
reactions back by 2,000 introduces new uncertainties:
will the products form efficiently, and can lower concentrations and volumes be handled without undue losses?
Also, we used a precipitation step to isolate AuCN, but
with such small amounts (1 µg of starting gold metal),
precipitates are more difficult to form and recover.
The synthesis was changed to reduce HAuC13 directly with a triphenylphosphine to the Au+ 1 necessary to
form clusters rather than producing AuCN from
HAuC13 . Three microliter reaction volumes were used
and a 75 % conversion of gold metal to gold clusters was
obtained. This was a higher efficiency than we achieved
earlier and the time for formation and purification was
cut from 1 day to 2 hours. Labeling of a test antibody
yielded ~ 80 % coupling. All of these tests used nonradioactive gold, but were then extended with similar
results to 199A1,1.

At end of bombardment (eob), ~98% of the gold
atoms are radioactive . After separating out the 198Pt
target, the gold was synthesized into undecagold clusters
(Au 11 , each containing 11 gold atoms). These were then
covalently bound to 17-lA monoclonal antibody (whole
IgG). After column chromatography purification, the
conjugate was tested by incubating with human colon
carcinoma cells (from cell culture) and with another human cell line as a control. After washing, the cells were
counted to find the amount of radioactive gold delivered
to each target. Serial dilutions were done to obtain a
binding curve and to vary the antigen-antibody ratio.
Excellent results were obtained which showed up to
41.3 % of the applied radioactivity bound to the tumor
cells, with about 2-4 % binding to the non-specific cells.
This demonstrates the high immunoreactivity retained by
the gold cluster conjugate . In particular, it shows that
the use of high-specific activity clusters can deliver more
radioactivity to tumor cells than with other conventional
techniques, which may have important therapeutic implications.
For comparison, radioactive clusters were prepared
that had 11100th the specific activity, so that about 1 out
of 100 gold atoms was radioactive. In an 11-atom gold
cluster, then no more than one of the gold atoms was radioactive. This was done to see if additional problems
occurred with the high-specific activity clusters; namely,
did they break down more rapidly, did they damage the
antibody more and cause greater loss of immunoreactivity and other such questions. The lower specific activity
preparation run in parallel demonstrated a high of 51 .4 %
binding to tumor cells with background non-specific attachment at again 2-4 %. The results were very similar
to the high-specific activity case and demonstrated that,
under these conditions, there seem to be no adverse

Testing the stability of high-specific activity 199Au11
clusters: they are remarkably stable
If all gold atoms are radioactive in the Au 11 cluster,
then is this cluster stable? Since the cluster contains
eleven radioactive atoms, when one decays ( 199Au has
a 3.1 day half-life), does the recoil break apart the cluster, or does the resultant mercury atom make the cluster
chemically unstable? Early disintegration of the cluster
would cloud its use as a therapeutic agent.
The stability of high-specific activity 199Au was assessed by gel filtration chromatography: various times
after preparation, the clusters were chromatographed on
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Table 5. Cell binding of high and low-specific activity
radioactive gold-antibody conjugates.
I99Au

tumor cells
(% Au bound)

non-tumor
cells

Low-specific activity

27

0.5

High-specific activity

37

3.9

High-specific activity 199Au cluster-antibody conjugates: tumor animal biodistributions
Nude mice were used with human colon carcinoma
xenografts. In these tests, the gold cluster conjugates
were again prepared at high -specific activity (all gold
atoms radioactive at eob) and 1/100 that activity for
comparison. Distribution was normal for an lgG conjugate in the blood, dropping from 7 .5 % id/g at 24 hours
to 1.0% at 96 hours . At 24 hours, the biodistribution
obtained is shown in Table 6 (using MAb 17-lA). Almost identical results were obtained with high- and lowspecific activity gold, indicating that the high-specific
activity gold immunoconjugates perform well and are not
subject to any significant additional degradation in vivo.
Compared to the well known In-DTPA conjugate
with the same antibody (17-lA, see Table 3), the gold
results were: blood l.5x more for Au, spleen 3.0x lower
for Au, stomach l.3x lower for Au, liver l.6x lower for
Au, kidney same, heart l. lx more for Au, lung l. lx
lower for Au, muscle l. lx lower for Au, bone 3.6x
lower for Au, tumor l. 9x lower for Au. In summary,
most organs showed typical IgG immunoconjugate distributions with the spleen, liver , and bone with notably
lower background using gold clusters. The tumor, however, showed lower accumulation than the In conjugate
in these tests. Nevertheless, the tumor to bone ratio was
1.7 for the In and 3. 3 for the Au, giving a 1.9x
improvement with the use of gold clusters for this most
radiosensitive tissue. These results are therefore encouraging, and tumor localization might be improved by
using different antibodies .

Table 6. Biodistribution of high- and low-specific
activity undecagold conjugates with MAb 17-lA at 24
hours after injection.
Tissue

Low-specific activity
(% id/gm)

High-specific
activity

Liver

5.2

4.4

kidney

10.3

9.9

lung

3.6

1.5

muscle

0 .8

0.6

bone

1.8

2.1

tumor

6.0

4.9

effects from use of the high-specific activity clusters .
Another set of experiments using 17-lA cell binding
is shown in Table 5. These results showed good activity
of the conjugates with minor differences between highand low-specific activities. The high-specific activity
gold had higher uptake, but also higher background ,
perhaps due to radiolytic effects or some degradation.

Blocking of non-specific sites by pre-injection of nonradioactive gold clusters

High-specific activity 199Au cluster-antibody conjugates: serum stability

Radioactivity found in other tissues besides the
tumor may be due to a number of factors : the antibody
may have cross-reactivity, simple dilution and diffusion,
metabolism of the conjugate, breakdown of the isotope
from the antibody so it is no longer tumor-targeted,
opsonization, aggregation of the conjugate which usually
leads to liver and spleen uptake, and stickiness of the
radioisotope and/or chelate moiety to non-specific areas.
In the case of gold clusters, it may be that one of these
factors, namely some affinity of the cluster itself for tissues, may lead to increased backgrounds . We, therefore, postulated that a pre-injection of non-radioactive
gold clusters may saturate these secondary sites and
reduce background when the radioactive cluster-antibody
was later injected. First, animals were tested for any
acute toxicity caused by intravenous gold cluster injection. It was found that death resulted in some animals
at a level of 100,000 times the amount of gold that
would be injected in a typical immunotherapy trial.

Another test that a potential therapeutic immunoconjugate must pass is that it be stable in serum. The highspecific activity gold cluster conjugates along with the
1/100 specific activity cluster conjugates (described
above) were incubated with fresh mouse serum and at
various times later passed over a gel filtration column.
If the radioactivity stayed with the IgG, the counts
would appear at the IgG column retention time . If the
gold-IgG conjugate had broken down in some way, some
radioactivity most likely would appear at other retention
times, indicating perhaps binding to serum albumin,
other blood components, or free gold. Both of these
preparations demonstrated excellent serum stability with
-95 % of the activity remaining with the lgG peak even
after 96 hours. Furthermore, the high-specific activity
preparation showed virtually identical behavior to the
1/100 specific activity conjugate. These results indicate
that serum stability of the gold clusters was acceptable.
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Table 8. Calculated dosimetry of 199Au using biodistributionobtained for 1251-NR-CE-01 antibody. Dose
to tumor expressed in cGy (1 cGy = 1 rad).

Table 7. Changes in biodistribution at 24 hours with a
preinjection of non-radioactive gold cluster (Au 11).
Tissue

Percent change with preinjection

blood

+52

spleen

-10

stomach

+9

intestine

+200

liver

-38

kidney

-39

heart

-1

lung

-18

muscle
bone

-12
+8

carcass

+35

F(ab) 2

Fab

at 300 cGy to whole body

1050

3780

2880

at 1200 cGy to kidney

4400

4500

1600

in Table 8. From these "extrapolated" data, it appears
that 199 Au .is very close to being useful in therapy, with
the F(ab)' 2 conjugate being the best choice. (A dose to
the tumor of 5,000 cGy is desirable). It should be
stressed that this calculation is inaccurate, since 1251 will
behave differently than 199Au, and so may the antibody .
It is shown, however , to at least give some idea of
dosimetry with 199Au in vivo.
Recalculation using other therapeutic isotopes
showed radioactive gold to be one of the 7 best choices
when compared to all other isotopes for therapy . Due
to its shorter beta range, it should be the isotope of
choice for treating micrometastases and small cell lung
carcinoma. Treatment of metastases is, in fact, probably
the best use of immunotherapy, where the antibodies can
track down spreading cells missed by surgery.
Using our actual biodistribution collected with
17-lA lgG conjugated to 199Au 11 , the dose to tumor at
bone marrow max tolerated dose (MTD) was calculated
at 1000-2000 cGy (Wessel s, personal communication);
this falls short of the requirement s for therapy .

+5

stumor

lgG

Non-radioactive gold clusters were, therefore, injected
at a level of 10,000 over the antibody conjugated gold.
The radioimmunoconjugate was injected 1 hour after the
blocking gold. This resulted in the following changes in
non-specific organ uptake 24 hours after injection,
shown in Table 7. This shows an improvement for most
tissues , especially the liver and kidney (38 and 39 % decrease, respectively). However, the intestine (a radiosensitive organ) localiz.ation increased by a factor of 2.
We can conclude from this study that some tissue backgrounds can be significantly reduced by a pre-injection
blocking procedure.

Reduction of kidney uptake
One feature of the gold clusters is the ability to alter
the organic shell surrounding the core of gold atoms.
This may be important in designing a material that has
improved biodistributions, namely that the uptake in
non-specific organs is reduced . Since the N-methylbenz.amide-derivatized triphenylphosphines that we have
normally used have given generally higher kidney accumulation of gold clusters and their conjugates than is
usually seen with DTPA conjugates, another derivative
was sought that would reduce kidney retention.
The elevated kidney uptake of gold clusters may be
due to the thiol content of kidney tissue and its strong
interaction with gold atoms. Another possibility is the
ionic interaction, which has been studied by others who
have shown that changing the isoelectric point by simple
chemical modification of antibodies (e.g ., by acetylation), alters kidney uptake (Tarburton et al., 1990). We
synthesized a cluster containing 21 COO- groups on its
periphery and found a dramatic effect on biodistribution
(of cluster alone, no antibody attached; shown in Table
9). Significant decrements of uptake in liver and kidney

Dosimetry calculation for 199Au immunoconjugates
Dosimetry calculations, that integrate radiation over
time and volumes, are important to predict the total dose
to a tumor versus that delivered to other organs and
whole body. This quantifies the results into terms that
assess whether a particular immunoconjugate will be
successful in therapy or whether normal tissue tolerance
will be exceeded before enough doses are delivered to
the tumor. Dr. Barry W. Wessels (George Washington
University) has calculated maximal tumor dose achievable for radioactive gold.
Calculated tumor doses using the Wessels and
Rogus dosimetry formalism (Wessels and Rogus, 1984),
with 199Au 11 "theoretically" conjugated to lgG , F(ab ')i,
and Fab are shown in Table 8. This uses a very good
distribution obtained by Beaumier with another antibody
(NR-CE-01) and isotope ( 1251), and doses are calculated
by substituting the properties of 199Au for 1251 (Yorke
et al., 1991). From those data, 199Au was substituted
as the isotope used to give the doses to the tumor shown
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conjugates, and although these were cleared by the reticuloendothelial system (RES), they showed virtually no
kidney uptake, typically 0.5-1.4 % id/gm. If RES uptake
could be blocked , colloidal gold may provide a viable
method of delivery since it avoids one of the problems
with the gold cluster work, namely high kidney uptake.
On the other hand, the liver is fairly radioresistant, and
whether blocking the RES improves dosimetry remains
to be seen.
Synthesis of other gold clusters to improve biodistributions

Table 9. Radioactive Au 11 tissue distributions for cluster with 1 amino group ( + 1 charge), and 21 carboxyl
groups (-21 charge), 24 hours after injection. No
antibody was attached.
Tissue

Aull
( + 1 charge)
% id/gm

Aull
(-21 charge)

per cent
change

blood

1.9

2.7

+42

spleen

7.5

3.5

-53

stomach

0.6

0 .9

+50

intestine

1.3

1.6

+23

liver

48.0

5.4

-89

kidney

78.2

17.2

-78

heart

1.9

2.5

+31

lungs

4.9

4.3

-12

muscle

0.6

0.8

+33

bone

3.1

1.6

-48

The gold clusters we have been using so far are
made with triphenylphosphine derivatives such as the
organic shell around the solid gold atom core. Even
though these clusters can contain charged or polar
groups and are very water soluble, the phenyl groups do
impart some hydrophobic character. This may contribute to some unwanted in vivo binding . Therefore,
we have investigated the synthesis of alkyl phosphine
clusters, which are extremely hydrophilic . These are
being studied further.

Single gold atom compounds: quest to improve biodistributions
In addition to the cluster approach, smaller, single
gold atom compounds may be made which can be covalently coupled to antibodies . While not delivering
multiple radioactive atoms per antibody, as with clusters,
this method would still use 199Au and retain the benefits
of this isotope. Accordingly, several mono-gold compounds were evaluated. One class:

Table 10. Biodistributions of radioactive Au 11 conjugated to antitumor antibody using clusters that had no
charge versus those with a -19 charge (carboxylated
cluster) .
Tissue

Aull
(0 charge)-Mab
(% id/gm)

Au 11
(-19 charge)-Mab

liver

10.5

9.2

kidney

25.3

26.9

bone

2.5

1.6

tumor

6 .8

5.8

Au[(RPh)i - CH 2 CH 2 - P(PhR)i],
where R was coo- or NH 2 and Ph = phenyl, was synthesized using radioactive gold. This class cleared the
blood slightly faster than Au 11(Coo-hi but showed
either higher kidney or liver accumulation. Other monogold compounds are being studied.

Colloidal gold

In vivo targeting of radioactive 15 run gold colloid
immunoconjugates in nude mice with human tumor
implants We have also tried intravenously administered
radioactive colloidal gold-monoclonal antibody conjugates. One might reject this approach a priori, since it
is known that colloidal material accumulates in the liver,
spleen, bone marrow, and lungs (the target is somewhat
determined by the size of the colloid). Also, the antibodies are adsorbed to the gold particles instead of being
covalently attached, and may be less stable in vivo than
the covalent conjugates. Nevertheless, colloidal gold
conjugates are widely used and have a potential advantage: each gold particle contains many gold atoms, e.g.,
-60,000 for a 15 nm particle, and so could deliver a
much larger dose per antibody than with single isotope-

(89 and 78 % reductions, respectively) were found with
the negatively charged cluster.
The immunoconjugate using this carboxylated cluster was tested to see if significant uptake in non-tumor
tissues (especially liver and kidney) could be effected.
To this end, two different radioactive clusters were synthesized and coupled to a monoclonal (BR-15-6A IgG).
Table 10 gives tissue distributions (mice, after 24
hours).
No significant changes were observed in this test;
therefore, we conclude that use of the carboxylated cluster has little effect on the biodistribution when attached
to lgG.
We also tested radioactive colloidal gold immuno249
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Table 11. Mouse biodistributions using 198Au-15 nm colloidal gold with either tumor-specific antibody or BSA
adsorbed (values are expressed as % injected dose per gram).
24 hours

96 hours

Tissue

F(ab)'rAu

Tumor

0.28 ± 0.27

0.11 ± 0.08

0.03 ± 0.01

0.04 ± 0.02

Blood

0.023 ± .001

0.023 ± .002

0.016 ± .003

0.017 ± .005

2.5

11.1 ± 2.6

14.3 ± 0.4

Stomach

0.38 ± 0.35

0.60 ± 0.69

0.05 ± 0.01

0.15 ± 0.15

Kidneys

1.10 ± 0.33

0.57 ± 0.05

0.73 ± 0.11

0.52 ± 0.07

Heart

0.15 ± 0.08

0.22 ± 0.01

0.15 ± 0.05

0.28 ± 0.08

Lung

0.88 ± 0.04

1.53 ± 0.23

1.40 ± 0.10

1.34 ± 0. 19

Muscle

0.06 ± 0.03

0.06 ± 0.03

0.06 ± 0.03

0.04 ± 0.01

Bone

4.79 ± 0.23

3.82 ± 0.39

4.47 ± 0.57

4.16 ± 0.41

Gut

0. 15 ± 0.07

0. 15 ± 0 .07

0. 14 ± 0.05

0.16 ± 0.06

Spleen

16.5

±

BSA-Au

F(ab)'rAu

BSA-Au

12.2

±

2.1

Liver

123. ± 10.4

81.1 ± 4.5

111.8 ± 4.1

76.2 ± 0.7

Carcass

0.84 ± 0.21

0.57 ± 0.04

0.71 ± 0.09

0.85 ± 0.23

single antibody conjugates. Anti-CEA F(ab)' 2 - 15 nm
198 Au was used and a BSA-15 nm 198Au conjugate was
also injected (no antibody) as a control; Table 11 shows
the results. From these data, it is clear that the colloidal
gold conjugates clear the blood quickly, and that there is
not much change in biodistribution from 24 to 96 hours.
An exception to the stable localization is the tumor,
where wash-off was substantial between 24 and 96
hours. It may also be noted that the specific conjugate
with antitumor F(ab)' 2 and the (control) BSA had almost
identical distributions, except at 24 hours there was
more gold in the tumor with the specific antibody . It
appears that the tumor binding or gold-antibody binding
is not stable in vivo over time, which would account for
the almost complete loss of gold from the tumor at 96
hours. As expected, the colloidal gold is largely accumulated in the liver and spleen, and secondarily in the
bone and lung. As with most experiments, many other
controls could be done; here, a non-specific antibody
conjugated to the gold would be an interesting comparison, but was not done in this pilot study .
In comparison to the undecagold conjugates, the
Au 11 was 243 times higher in the blood at 24 hours , and
had a lower amount in the liver by -12 times ; Au 11
was 2 times lower in the bone; kidney accumulation was
-16 times higher for the Au 11 { for lgG; worse for Fab'
and F(ab)' 2 }, and the tumor localization was 30 times
higher with the Au 11 . We may conclude from this study
that the in vivo vascular use of colloidal gold immunoconjugates is much worse than with the Au 11 conjugates,
and that colloidal gold cannot be considered for intra-

venously administered immunotherapy applications, in its
present formulation, since it falls far short of the necessary requirements.
Bladder carcinoma
A special case that avoids many of the intravenous
delivery problems associated with antibody targeting in
vivo was proposed by de Harven et al. (1992) for the
therapy of superficial urinary bladder carcinoma: a
radiogold antibody conjugate would be intravesically
instilled via catheter into the bladder for 0.5 to 1 hour,
then washed out, so only that taken up by the cells
would remain. De Harven et al. (1992) found that biopsied tumor cells from patients took up 16 nm - Mab
48-127 antibody conjugates rapidly; non-tumor cells
showed virtually no uptake . Gold particles were found
not only on the surface of the tumor cells , but also in
the cytoplasm. This internalization of surface antigen/
antibody complex has been noted with many (but not all)
tumors/antigens/antibodies. Quantification of this uptake
was done by counting gold particles in thin sections,
leading to a calculation of 1,000 to 12,700 gold particles
per cell (E. de Harven, personal communication). In
this application, one could consider using 16 nm colloidal gold conjugates, as well as other colloidal gold sizes,
or the covalent gold clusters, undecagold and Nanogold .
Each formulation is different and it is difficult to predict
a priori which will perform the best. In vivo stability of
these conjugates is important and needs further study.
It was found , however, that the performance of the
colloidal gold conjugate was unaffected by urine pH
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conditions (E. de Harven, personal communication).
A pilot study with another antibody and 111In has
been reported using intravesical administration.
Although the dose calculated that might be delivered by
this antibody from the uptake measured fell below therapeutic usefulness, virtually no radioactivity was detected
in the general circulation (Bamias et al. , 1993).
As with most antibody delivery systems, the antibody itself strongly dictates the performance of the conjugate. MAb 48-127 was developed by Fradet et al .
(1986) after considerable screening. It is highly specific
for bladder tumor cells, with negligible reactivity with
normal bladder epithelium. It targets the glycoprotein
gp 54 (molecular weight = 54 kD) specifically expressed on bladder tumor cells. De Harven et al. (1992)
have provided scanning electron microscopic evidence
that this antibody reacted uniquely with superficial urothelial cells with microvilli (i.e . , the transformed cells),
and not with normal urothelial cells, thus making it
attractive for therapy.

gold, or 0.07 particles per cell for high-specific activity
gold .
Although it appears easily possible to deliver tumoricidal doses by the means proposed, effective therapy is
usually limited by tumor to non-tumor ratios . This calculation merely shows that 15 nm radioactive gold
immunoconjugates are very potent, and it must be thoroughly demonstrated that they can be kept out of healthy
tissue to prevent its excessive damage.
Another consideration is the dose to normal tissue
incurred by the instillation of radioactive conjugate and
irradiation during the incubation time. Since the range
of the (J' s is short , only a shell in contact with the urothelium would contribute. A rough estimate would be a
few percent of the material for 0.5 hour. If specific uptake was -1-3% id/g, this would act over the gold's
radioactive life, or - 10 days , so that - 200 times the
background initial dose should be specifically delivered.
More careful dosimetry should be done to calculate this
factor.

Dosimetry for colloidal gold

Twnor cell binding using radioactive colloidal gold
conjugates

An advantage of colloidal gold for therapy 1s its
size. A 15 nm gold particle contains -60 ,000 gold
atoms and each immunoconjugate molecule may, therefore, deliver up to 60,000 times the dose of single antibody -radionuclide conjugates typically used. An estimate of the dose delivered to the tumor cells is as follows: since the number of colloidal gold particles per
tumor cell was measured to be between 1,000 and
12,700 , an average of 5,000 is used here for this calculation. Assuming a 1 g tumor mass, this would contain
- 8 x 109 cells . The number of gold atoms contained
therein would be 5,000 x 60 ,000 times this , or 2.4 x
10 18 , or 8 x 10-4 g of gold. The total average (3 energy
absorbed in tissue for an isotope depends upon the value
of o (gm·rad/µCi·hr),
which is 0.664 and 0 . 182 for
198Au and 199 Au, respectively (Kocher, 1981). Assuming low-specific activity 198Au was used , 8 x 104
µCi/mg, the dose to the tumor would be in 24 hours:

In order to pursue this , in vitro cell binding of
radioactive 15 nm colloidal gold conjugates was performed. This was done to obtain a quantitative measure
of the binding (or total uptake) of tumor versus nontumor cells . From these measurements, tumor to nontumor ratios may be calculated, as well as total
radioactive gold delivery . Once these figures are
known , a project ed dosimetry calculation can be made
to estimate the dose delivered to a tumor mass, whether
it would be therapeutic, and whether this strategy would
be efficacious.
It should be cautioned that further
animal studies or other in vivo experiment s are required
to fully evaluat e this method, since all too frequently , in
vitro results do not translate directly to the in vivo
response .
Two mg of gold foil was irradiated in a nuclear
reactor, dissolved in aqua regia , dried, dissolved in concentrated HCl, dried , then resuspended in water, to produce low-specific activity gold , 80 mCi/mg, in the form
of chloroauric acid . This was used to form 15 nm colloidal gold by the citrate reduction method . Conjugation
to MAb 48-127 (specific for human superficial bladder
carcinoma) proceeded by adjustment of the pH of the
gold to 6-9 (in various experiments), and adding an
amount derived from the salt protection graph; 12 µglml
was used . The conjugate was then further protected
with BSA (1 % final), and purified from unbound antibody by centrifugation . Cell binding experiments were
carried as described earlier. Binding results are illustrated in Figure 7.
Frequently , in this type of assay, the control cell

Dose (in rad) = d · µCi ·hr/gm
0 .664 · (8 x 104 µCi/mg) (0.8 mg gold) (24 hr)/
(1 gm tissue);

=

so:

Dose = 1 x 106 rad.

If high-specific activity gold ( 199 Au) were used, this
would be 7 x 108 rad . Since the effective tumoricidal
absorbed dose is -10,000 rad (Bigler et al., 1988), the
dose delivered by the gold particles exceeds this by a
factor of 100 for the low-specific activity, or 70,000 for
the high-specific activity . For a 15 nm gold particle, a
therapeutic dose of 10,000 rad can, therefore, be delivered by 50 particles per cell for low-specific activity
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Antibody/gold conjugate dilution
Figure 7. Cell binding ofMAb 48-127 adsorbed to radioactive 15 nm 198Au colloid. T24 is the antibody target cell,
a human superficial bladder carcinoma, and WM164 is a non-specific human cell line.

directly translate into identical in vivo results, and
further testing in animal models is required.

binding remains approximately fixed , as it does here , but
the specifically bound antibody shows a more sigmoidal
shape with lower binding at low antibody dilution (where
there is antibody excess), and an asymptotically
approached higher value at high antibody dilution, where
there is antigen excess , and nearly all active antibodies
can bind.
In this cell binding experiment, - 200 µCi/ml was
used; 50 µ1 was applied to 250,000 cells. Sixteen percent uptake corresponds to - 3,000 gold particles per
cell in the first dilution and a dose delivered of 9 x 105
rad (in 24 hours). This exceeds the calculated therapeutic level, so less gold or lower specific activity gold
could be used. The tumor to non-tumor ratio was
-6.8, so for safe therapy, the dose would have to be
reduced to limit that received by normal tissue . It
should be pointed out that such in vitro results do not

Conclusion
Radioactive Au-198/199 has excellent radionuclidic
properties for therapy to locally irradiate and kill tumor
cells. Methods have been developed to produce and purify these isotopes in high yield. The use of gold
coupled to antitumor antibodies has been studied using
various gold formulations from single gold atom compounds to gold clusters to gold colloids. Studies were
conducted in vitro and in vivo and indicate some of the
problems and promises of the various gold conjugates.
Preliminary data suggest that immunotherapy of bladder
carcinoma may be feasible using radioactive gold .
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Reviewer ill : The data presented in Table 2 shows
good specificity as claimed in the text; however, the
percentage of binding is very low . The vast majority of
the activity does not bind to the tumor cells. Has the
immunoreactivity of 85 % of the MAb been lost when
the gold is conjugated to the MAb?
Author: Many MAbs show decreased immunoreactivity
when radiolabeled with various chelators and conjugate
moieties, compared to low level 1251 labeling. Values of
immunoreactivity of 15-25 % are not uncommon, whereas some antibodies retain high levels ( > 75 %). The
17-lA test antibody used here unfortunately falls in the
first category, but follows along with results seen for
many other chelators and metals seen with this antibody.
Reviewer ill: A higher number radioactive gold molecules per cluster does not mean that there will be a better delivery of radioactivity to tumor cells . What is
important is the relative localization to tumor versus normal cells. The amount of activity per MAb molecule
may not be relevant. I am not aware of any system in
which the amount of MAb administered to a patient saturates the tumor binding sites.
Author: The tumor to non-tumor ratio is one of the
most important values ; having more gold atoms per antibody should not affect the antibody distribution, so it
would not alter this ratio. Graded dose studies have indicated that tumor antigen is not saturated, so administering more antibody with one radionuclide per antibody
or administering lower antibody amount with more radionuclides per antibody should be equivalent. A main
problem with radioimmunotherapy is that the biodistributions achieved yield a tumor to non-tumor ratio too low
for effective therapy in many cases . Other multistep
strategies (i.e., avidin-antibody is first administered,
then after waiting - 5 days, since the non-tumor washout is faster than that on the tumor, a biotin-radionuclide
is administered which quickly localizes and capitalizes
on the better tumor to non-tumor ratio) typically have
very reduced final radionuclide uptake. In these cases,

Discussion with Reviewers
Reviewer ill: The author states that gold-199 emits a
gamma energy suitable for imaging . While gold-198's
gamma energy of 412 keV can be imaged, its energy is
considerably higher than that normally used for imaging
studies.
Author: Gold-198 is not optimal for imaging, but
would permit localization studies to be done in a patient
before administering high therapeutic doses, using the
same isotope and labeling method. Gold-199 may also
be used, which has lower gamma energies, 159 and 208
kV (see Table 1).
Reviewer III:
The tumor accumulation of a
radiolabeled MAb is dependent on the form; while
F(ab')z fragments may yield peak accumulation at 22
hours, it is not the case for intact IgG, which often
yields higher levels in the tumor at 48 hours than at 24
hours.
Author: It is true that the smaller antibody fragments
localize more quickly, but the actual time seems to be
dependent on the antibody (fragment and subclass), animal, and perhaps, even the conjugate moiety. Four anti-
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make the dosimetry worse, not better .
Author: With the colloidal gold-F(ab'}i, ~ 100% i.d./g
localized in the liver; this was most of the radioactivity.
To make this preparation useful, it would appear that the
liver uptake should be blocked in some fashion, and
more would then be expected on the tumor. This parallels the work with liposome delivery, where most goes
to the liver, and after RES evasion or blocking, more
goes to the tumor with better tumor to non-tumor ratios.

if each antibody or directing moiety contained more
radionuclides, the delivered dose could be boosted to
therapeutic levels.

Reviewer ill:
The text states that the low specific
activity preparations had 51.4% binding to tumor cells;
Table 5 shows 27 %. Why do the lower specific activity
conjugates have less binding to the tumor cells than the
high specific activity conjugates?
Author: Each cell binding experiment is run in duplicate, so the values given are the average. Separate
experiments often give different average values, indicating the variability of the assay or preparation . Given
this, the difference in the high and low specific activity
preparations (37% and 27-51 %, respectively), does not
appear to be highly significant without further measurements and statistics.

Reviewer ill : In Table 11, the appropriate control for
these studies is an F(ab')i molecule from a control antibody, not BSA.
Author: As with all experiments, there are many controls that one can imagine. Initial limited controls are
often chosen because of availability, as was done here.
The use of BSA has some merit in that it does not have
a targeting property , it is about the same weight as the
antibody fragment, and its in vivo properties are known.
Further controls should include the one you suggest.

Reviewer ill: The author states that the use of pretargeted clusters shows an improvement for most tissues .
What is very notable is that the pretargeting resulted in
a 200 % change in the intestines which are a radiosensitive organ.
Author: This is an important observation, but the
experiment illustrates that pretargeting (administration
first of non-radioactive gold clusters) can significantly
change the biodistribution.

Reviewer ill: The author should note that the internalization of MAbs is dependent to a large degree on the
MAb, not the tumor type . The fact that many tumors
will internalize a given antibody is a property of the
MAb and the antigen primarily, not the tumor type.
Author: Except that different tumor types often have
different antigens. It is interesting that for many tumor
types, antibodies have been isolated that are highly internalized (while some are not) , so use of internalization
for delivery appears feasibly in a general way.

Reviewer ID: Dosimet ry calculations are made by
extrapolating from the biodistribution of iodinated MAb.
These estimates can not be accurate because of the localization of the radiometals and radioactive gold to normal
tissues is very different from that of the iodine, which
does not localize in many normal tissues. Any estimates
of dosimetry of normal tissues will be inaccurate; one
example is the dosimetry of normal kidney where the
radioactive gold localizes at higher levels than even
indium .
Author: There are clear limitation s, as you point out,
of taking the biodistribution for an iodinated antibody
and theoreti cally substituting gold for the iodine. The
point of this exercise was more to compare the dosimetry of various isotopes, assuming the antibody distribution was the same. Conjugation techniques and chelators have been improved to the point where it is, in
fact, possible to get similar biodistributions with the
same antibody and different radionuclides, and it may be
also possible to develop gold to this point.

Reviewer III: What is the stability in vivo of the gold
colloid MAb preparations?
Author: Serum stability studies were not done, and further experiments would have to be designed to determine
the fate of the antibody-gold conjugates in vivo.
Reviewer ID : The calculations for the tumor dosimetry
are interesting, but what about the dose to normal bladder from the radioactivity in the fluid instilled?
Author: This is an important point, since if 10 % of the
radioactivity was taken up by the tumor cells, then the
radiation they would receive over 10 hours would be the
same (roughly) as that received by normal cells by the
complete preparation (100%) in 1 hour when it is instilled and is incubating, before flushing. The situation
would be better, however, since the gold radiation has
a range of only 460 µ.m, so that having it on or in the
tumor cell would have a direct effect, whereas gold dispersed in a bulk fluid ( ~ 100 ml) in the bladder would
mostly be attenuated and diluted and should have a minimal effect. Further dosimetric calculations must be done
to quantitate this initial dose, but it is clear that a short

Reviewer III: If the RES system can be effectively
blocked; what will happen to the gold labeled MAb?
How will this affect the normal tissue distribution , and
thus, the toxicity to normal tissues? The liver is a fairly
radioresistant tissue. The blocking of the RES may
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incubation time, and, as usual, a high tumor to nontumor uptake ratio, would improve the tumor specific
dose.
Reviewer ID: 0ne cannot determine the tumor to nontumor ratio based on in vitro studies. The biodistribu tion is rarely as good as the in vitro binding studies.
Author : Although in vivo distributions are generally
worse than in vitro results , the in vitro studies have their
place in screening preparations , and in calculating tumor
cell to non-tumor cell ratios at that point.
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